BioSpace News Archive

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc.

Aqua-Yield, the leading nanoliquid company for agricultural production worldwide, today announced the close of its Series A investment round of $23M.

The 3D cell culture market is seeing a steady development because of the elements, as tremendous ventures by life science organizations for R&D, advancement of robotized enormous scale cell culture frameworks, and rising requirement for organ replacement.

Lyophilization has been popularly employed by the pharmaceuticals industry in parenteral product development.

MolecuLight Inc. announces that its MolecuLight wound imaging platform is featured in 8 presentations and posters at Wounds Australia 2022.

Microbot Medical Inc., announced that Harel Gadot, Chairman, President and CEO, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference being held in NYC.

ProMIS Neurosciences, Inc. announced that it has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022.

Rubius Therapeutics, Inc. announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.

IsoPlexis Corporation announced the publication of initial data off its CodePlex platform in the journal Scientific Reports carried out by researchers at the Shanghai Institute of Hematology.

Akouos, Inc. (NASDAQ: AKUS), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF, a gene therapy intended for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss.